

Special Issue

Novel Vaccines and Vaccine Technologies for Emerging Infections

Message from the Guest Editors

This Special Issue aims to provide a platform for sharing the most recent advances in the development of novel vaccine candidates, platforms, and technologies for combating emerging infections and future pandemics. More specifically, we welcome the contribution of original research articles, reviews, and commentaries that address the following topics:

- New vaccine platforms, technologies, and adjuvants;
- Universal vaccine candidates;
- Mucosal vaccines and vaccination;
- Modular vaccine platforms for rapid biomanufacturing and expedited regulatory approval;
- Vaccines as a tool for antimicrobial resistance;
- AI application in the rapid identification of novel vaccine antigens;
- Immune correlates of vaccine-induced protection;
- Systems immunology and vaccinology;
- Novel in vitro and in vivo assays and models for assessing vaccine-induced immunity and predicting vaccine efficacies;
- Vaccine bioprocess and manufactures.

Guest Editors

Dr. Wangxue Chen

Dr. Xuguang Li

Prof. Dr. Amine A. Kamen

Deadline for manuscript submissions

closed (30 September 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/183532

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).